Cirius Therapeutics, Inc.   Report issue

For profit Phase 3
Founded: Kalamazoo MI United States (2015)

Organization Overview

First Clinical Trial
2016
NCT02784444
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Cirius Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Azemiglitazone (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Fatty Liver (Phase 3)

Liver Diseases (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1